Lung Cancer Cell Line Nº StudiesStrainNº Mice H44113Athymic nude119 A5492CB-17scid15 Calu-62CD-1 nu/nu25 H16501Athymic nude8 H19751Athymic nude8 H21226Athymic.

Slides:



Advertisements
Similar presentations
Estimating the False Discovery Rate in Multi-class Gene Expression Experiments using a Bayesian Mixture Model Alex Lewin 1, Philippe Broët 2 and Sylvia.
Advertisements

Sources and effects of bias in investigating links between adverse health outcomes and environmental hazards Frank Dunstan University of Wales College.
Data Mining Methodology 1. Why have a Methodology  Don’t want to learn things that aren’t true May not represent any underlying reality ○ Spurious correlation.
Analysis of variance (ANOVA)-the General Linear Model (GLM)
Response Optimization in Oncology In Vivo Studies: a Multiobjective Modeling Approach Maksim Pashkevich, PhD (Early Phase Oncology Statistics) Joint work.
Departments of Medicine and Biostatistics
Modelling Immune reconstitution in paediatric bone marrow transplants London Pharmacometrics Interest Group 1 st March 2013 Rollo Hoare.
Capecitabine: a pharmacokinetic model derived from its clinical use. Aldaz A. 1, Zufía L. 1, Bueno L. 2, Sayar O. 2 1 Pharmacy Department, University Hospital.
The Influence of Social Goals and Perceived Peer Attitudes on Intentions to Use Tobacco and Alcohol in an Adolescent Sample Elisa M. Trucco, B.A. and Craig.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 12: Multiple and Logistic Regression Marshall University.
Regression and Correlation Methods Judy Zhong Ph.D.
Bayesian Hierarchical Models of Individual Differences in Skill Acquisition Dr Jeromy Anglim Deakin University 22 nd May 2015.
1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.
BPS - 3rd Ed. Chapter 211 Inference for Regression.
Results: In the presence of PD measurements, PK data provided little additional information. By a limited PD sampling the number of patients on target.
Applying SGP to the STAR Assessments Daniel Bolt Dept of Educational Psychology University of Wisconsin, Madison.
Modeling of Longitudinal Tumor Size Data in Clinical Oncology Studies of Drugs in Combination N. Frances 1, L. Claret 2, F. Schaedeli Stark 3, R. Bruno.
Background Objectives Data Simulation in human Conclusion -F14512, a polyamine-vectorized anti-cancer drug which combines an epipodophyllotoxin core targeting.
Results: Accuracy and precision expressed as MPE and RMSE was better for the proposed model compared to the Sam and Staatz models. Graphical diagnostics.
CORRELATION: Correlation analysis Correlation analysis is used to measure the strength of association (linear relationship) between two quantitative variables.
Study Design & Population A retrospective cohort design was applied to the Medicaid administrative claims data of youth continuously enrolled in a Mid-Atlantic.
AN EXAMPLE OF APPLICATION OF THE POPULATION APPROACH TO TOXICOLOGICAL STUDIES F. Fiorentini 1, M. Simeoni 2, I. Poggesi 1, G. Westerberg 1, M. Rocchetti.
Logistic Regression. Linear regression – numerical response Logistic regression – binary categorical response eg. has the disease, or unaffected by the.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 11: Models Marshall University Genomics Core Facility.
Multivariate selective editing via mixture models: first applications to Italian structural business surveys Orietta Luzi, Guarnera U., Silvestri F., Buglielli.
Model-based dose selection for next dose- finding trial 1. Introduction Exploratory clinical development trials often include biomarkers or clinical readout.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Estimating the uncertainties in the products of inversion algorithms or, how do we set the error bars for our inversion results? Emmanuel Boss, U. of Maine.
Statistical Analysis for Expression Experiments Heather Adams BeeSpace Doctoral Forum Thursday May 21, 2009.
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
BPS - 5th Ed. Chapter 231 Inference for Regression.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 13: Multiple, Logistic and Proportional Hazards Regression.
Exposure Prediction and Measurement Error in Air Pollution and Health Studies Lianne Sheppard Adam A. Szpiro, Sun-Young Kim University of Washington CMAS.
Confidential and Proprietary Business Information. For Internal Use Only. Statistical modeling of tumor regrowth experiment in xenograft studies May 18.
Logistic Regression: Regression with a Binary Dependent Variable.
 Adaptive Enrichment Designs for Confirmatory Clinical Trials Specifying the Intended Use Population and Estimating the Treatment Effect Richard Simon,
Imputation method to correct overestimated shape parameter of
Comparing Theory and Measurement
EHS 655 Lecture 15: Exposure variability and modeling
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Figure 2 Multiscale modelling in oncology
Background and Objectives
Design and Analysis of Crossover Study Designs
CHAPTER 26: Inference for Regression
RAT SIMULATION RESULTS HUMAN SIMULATION RESULTS
W.W. Hope, G.L. Drusano  Clinical Microbiology and Infection 
Longitudinal Analysis Beyond effect size
Some Design Recommendations For ASAP Studies
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
Volume 3, Issue 1, Pages (January 2013)
Basic Practice of Statistics - 3rd Edition Inference for Regression
Fixed, Random and Mixed effects
Product moment correlation
Lea Goentoro, Marc W. Kirschner  Molecular Cell 
Volume 5, Issue 4, Pages e4 (October 2017)
Volume 91, Issue 5, Pages (September 2016)
Volume 7, Issue 3, Pages e12 (September 2018)
Danni Yu Eli Lilly and Company (Tue)
3.2. SIMPLE LINEAR REGRESSION
Statistics Time Series
Chapter 6 Logistic Regression: Regression with a Binary Dependent Variable Copyright © 2010 Pearson Education, Inc., publishing as Prentice-Hall.
Parallelization and High-Performance Computing Enables Automated Statistical Inference of Multi-scale Models  Nick Jagiella, Dennis Rickert, Fabian J.
Volume 111, Issue 5, Pages (September 2016)
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.
Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.
ANALYZING TUMOR GROWTH
TAE-684 effectively inhibits the growth of H3122 in vivo.
European Urology Oncology
Presentation transcript:

Lung Cancer Cell Line Nº StudiesStrainNº Mice H44113Athymic nude119 A5492CB-17scid15 Calu-62CD-1 nu/nu25 H16501Athymic nude8 H19751Athymic nude8 H21226Athymic nude56 HCC8271CB-17scid8 Typical Effects Random Effects Exploring Inter-study variability in the context of modeling unperturbed xenograft data M Garcia-Cremades 1, V Mangas-Sanjuan 1, IF Troconiz 1, G Mo 2, C Pitou 2, PW Iversen 3, JE Wallin 2 BACKGROUND Pharmacokinetic/Pharmacodynamic characterization of anti-tumor drug effects using xenograft studies is an important process during early stages of oncology drug development. A common feature in those studies is the presence of experimental variability (i. e., same tumor cell lines), and it is not uncommon to note discrepancies in model-related parameters and response outcomes (i.e., % tumor growth inhibition). Proper characterization of different levels of variability (individual and experimental) may facilitate interpretation of individual experiments, as well as optimal design. The objective of this work is to quantify the extent and the impact of inter-study variability on the model parameters reflecting initial tumor conditions (TS 0 ) and proliferation rate (λ 1 ). 1 Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain 2 Global PK/PD & Pharmacometrics, Eli Lilly and Company 3 Lilly Research laboratories, Eli Lilly and Company METHODS Longitudinal tumor volume data from animals (n=239) that received saline administration were used for this analysis. The selected analysis dataset represent different lung cancer tumour cell lines (n=7). For each type of cell line the number of experiments varied from 1 to 13 (Table I). All the analyses were performed with NONMEM 7.3. Different structural models were fit to the data to characterize the unperturbed tumour growth kinetics (Table II). Once the base population model was selected for each cell line, the study variable was incorporated into the model either as a non-ordered categorical covariate, or as second level of variability through the $LEVEL functionality available in NONMEM 7.3 (Figure I). RESULTS The unperturbed tumor growth model proposed by Simeoni et al.[1], provided a fair description of the data in all the seven different tumor cell lines. Including the study variable as second level of variability was significant (p<0.001) in those studies with more than three repeated experiments. Table 2 shows the -2LL for each developed model in those cell lines where inter-study variability was statistically significant (Table III). CONCLUSION This analysis shows that inter-study variability is present in typical xenograft experiments with a moderate magnitude and can be detected with precision in cases with at least three repeated experiments. Current available tools in Pharmacometrics allow proper handling of study effects beyond the covariate effects. Ongoing research focuses on the role of study effects in the perturbed growth model, and its similarities across different types of cancers. Reference Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M. Cancer Research 64: Estructural Models Exponential Logistic Simeoni Hanfeldt Tumour growth data Structural model Non-ordered categorical covariate TVKPRL=  1 IIVKPRL=  2 IF(STUDY.EQ.2) IIVKPRL=  3 ……………………. IF(STUDY.EQ.N) IIVKPRL=  N KPRL=TVKPRL x EXP(ETA(1) x IIVKPRL) $OMEGA 1 FIX $LEVEL functionality KPRL=  1 x (EXP(ETA(1) +ETA(N) $OMEGA 0.3 ……………….. $OMEGA 0.1 $LEVEL STUDY=(N[1]) Cell Lines ParameterH441A549Calu-6H1650H1975H2122HCC827 TS 0 (mm3) KP (days -1 ) SCL w 2 TS0 (%) w 2 KP (%) w 2 SCL (%) w 2 TS0_st (%) w 2 KP_st (%) w 2 SCL_st (%) Residual error (log mm 3 )* Model StructureH441 [-2LL]H212 [-2LL] Base model Differences at typical behavior on T0 & KP Mixture Model (Two populations in TS0) Mixture Model (Two populations in KP)* $LEVEL en TS $LEVEL in TS0 & KP Mixture Model (KP) & $LEVEL (TS0 & KP)-- Figure I. Modelling workflow. Table II. Models for unperturbed tumour growth Table I. Raw data Table III. Models for unperturbed tumour growth The magnitude of the inter-study variability in TS0 and Kp were estimated between % and was in the same range compared to the inter-animal variability (10-42%) (Table IV). In Figure III the pc-VPC for each lung tumour-type cell line using the final Simeoni’s model is shown. Figure IV represents the proliferation rate parameter of each cell line and the overall variability estimated based on the number of studies performed. Table IV. Models for unperturbed tumour growth Figure II. Levels of model variability. Simulations of Tumour growth (95%), for those cell lines including interstudy variability, taking into account (a) interindividual, interstudy and residual variability of the variability (green shadow profile), (b) interindividual and interstudy variability and (c) interindividual variability. Simulation with interindividual, interstudy & residual variability Simulation with interindividual & interstudy variability Simulation with interindividual variability H441H2122 TS0 corresponds to base tumour volume, Kp represents the proliferation rate constant, SCL is a threshold tumor volume at which the tumor growth switches from exponential to linear. W2 corresponds to the inter-animal variability of each parameter, being w2Parameter_st, the interstudy variability associated to each parameter with the LEVEL function Figure III. Model evaluation. Prediction corrected Visual Predictive Check for each lung cancer tumour cell lines. Figure IV. Estimated proliferation rate parameter for each cell line and different tumour types. The size of the circle represents the overall parameter’s variability and the color intensity the number of studies used for parameter estimation.